Patients with higher populations of podoplanin-positive CAFs exhibit worse outcomes after GFT treatment; this finding was supported by the observation of increased ERK1/2 pathway activity in GFT-treated cancer cells cocultured with podoplanin-positive CAFs [110]. This evidence concerns the gene MAPK3 and cancer.